• CanSinoBIO signed a non-binding letter of intent with Pakistan’s AGP to pursue opportunities for its 13-valent pneumococcal conjugate vaccine, PCV13i, in Pakistan.
• Parties will assess development and market-access steps to support future availability of PCV13i in Pakistan.
• Deal expands CanSinoBIO’s South Asia partnership footprint, building on earlier Pakistan cooperation on local fill-finish of its COVID-19 vaccine in 2021.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.